Compare Pfizer with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs SUN PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER SUN PHARMA PFIZER/
SUN PHARMA
 
P/E (TTM) x 30.6 59.0 51.7% View Chart
P/BV x 7.8 4.3 180.7% View Chart
Dividend Yield % 0.9 0.9 95.6%  

Financials

 PFIZER   SUN PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-21
SUN PHARMA
Mar-21
PFIZER/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs5,875654 898.7%   
Low Rs3,833339 1,132.1%   
Sales per share (Unadj.) Rs489.3139.6 350.5%  
Earnings per share (Unadj.) Rs108.89.5 1,142.3%  
Cash flow per share (Unadj.) Rs132.718.2 729.4%  
Dividends per share (Unadj.) Rs35.007.50 466.7%  
Avg Dividend yield %0.71.5 47.7%  
Book value per share (Unadj.) Rs523.1193.6 270.1%  
Shares outstanding (eoy) m45.752,399.34 1.9%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x9.93.6 279.1%   
Avg P/E ratio x44.652.1 85.6%  
P/CF ratio (eoy) x36.627.3 134.1%  
Price / Book Value ratio x9.32.6 362.2%  
Dividend payout %32.278.8 40.9%   
Avg Mkt Cap Rs m222,0631,190,430 18.7%   
No. of employees `000NANA-   
Total wages/salary Rs m3,61168,622 5.3%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m22,386334,981 6.7%  
Other income Rs m8118,592 9.4%   
Total revenues Rs m23,197343,573 6.8%   
Gross profit Rs m7,12441,616 17.1%  
Depreciation Rs m1,09420,800 5.3%   
Interest Rs m1541,414 10.9%   
Profit before tax Rs m6,68727,994 23.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7115,147 33.2%   
Profit after tax Rs m4,97622,847 21.8%  
Gross profit margin %31.812.4 256.2%  
Effective tax rate %25.618.4 139.2%   
Net profit margin %22.26.8 325.9%  
BALANCE SHEET DATA
Current assets Rs m19,247304,421 6.3%   
Current liabilities Rs m7,743161,456 4.8%   
Net working cap to sales %51.442.7 120.4%  
Current ratio x2.51.9 131.8%  
Inventory Days Days75149 50.3%  
Debtors Days Days299 2.1%  
Net fixed assets Rs m13,277336,682 3.9%   
Share capital Rs m4582,399 19.1%   
"Free" reserves Rs m23,473462,229 5.1%   
Net worth Rs m23,930464,628 5.2%   
Long term debt Rs m08,981 0.0%   
Total assets Rs m32,524641,103 5.1%  
Interest coverage x44.520.8 213.8%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.70.5 131.7%   
Return on assets %15.83.8 416.8%  
Return on equity %20.84.9 422.9%  
Return on capital %28.66.2 460.4%  
Exports to sales %1.50-   
Imports to sales %2.30-   
Exports (fob) Rs m339NA-   
Imports (cif) Rs m510NA-   
Fx inflow Rs m33984,493 0.4%   
Fx outflow Rs m51030,334 1.7%   
Net fx Rs m-17154,159 -0.3%   
CASH FLOW
From Operations Rs m4,27361,704 6.9%  
From Investments Rs m-4,6885,362 -87.4%  
From Financial Activity Rs m-15,711-59,805 26.3%  
Net Cashflow Rs m-16,1265,964 -270.4%  

Share Holding

Indian Promoters % 0.0 54.5 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 17.3 34.5 50.1%  
FIIs % 2.2 14.4 15.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 45.5 79.3%  
Shareholders   125,287 662,384 18.9%  
Pledged promoter(s) holding % 0.0 5.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   CIPLA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    AUROBINDO PHARMA    



Today's Market

Sensex Ends 150 Points Lower, Nifty Falls Below 15,800; FMCG & Banking Stocks Witness Selling(Closing)

After opening deep in the red, Indian share markets recovered most of the losses as the session progressed but still ended on a negative note.

Related Views on News

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates (Views On News)

Jul 30, 2021

Here's a rundown on Sun Pharma's June quarter results.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

The Greatest Dividend Stock of All Time is...(Views On News)

Jun 16, 2022

Prudent investors should consider dividend aristocrats to create passive, predictable, and growing income to rely on whether the market moves up or down in these uncertain times.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jun 29, 2022 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS